- Epic’s non-cutting technology to modulate the epigenome advances with the addition of new hypercompact Cas effectors and potent gene activators -SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins,.
15.08.2022 - All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs.